Results 121 to 130 of about 2,763,321 (346)

Breast cancer stage and molecular subtype distribution: real-world insights from a regional oncological center in Hungary

Discover Oncology
Objective Examining the distribution of breast cancer (BC) stage and molecular subtype among women aged below ( 65 years) the recommended screening age range helps to understand the screening program's characteristics and contributes to enhancing the ...
Judit Tittmann, Tamás Ágh, Dalma Erdősi, Bettina Csanády, Erika Kövér, Antal Zemplényi, Sándor Kovács, Zoltán Vokó   +7 more
doaj   +1 more source

OP105 Gaps, Challenges And Priorities For Neurodegenerative Disease Research And Health Technology Assessment [PDF]

, 2022
Fatima Salih, Angela C. Bradshaw, Lewis Killin, Nina Coll, Carlos Díaz, Ana Diaz‐Ponce, Dianne Gove, Dalia Dawoud   +7 more
openalex   +1 more source

Networked Living: a new approach to teaching introductory ICT [PDF]

, 2006
The course T175 Networked Living is a 300 hour, multiple media, distance learning course offered by the UK Open University. The first presentation of the course, in 2005, attracted over 1600 students.
Bissell, Christopher, Kear, Karen
core  

Using health technology assessment to assess the value of new medicines: results of a systematic review and expert consultation across eight European countries [PDF]

, 2017
Although health technology assessment (HTA) systems base their decision making process either on economic evaluations or comparative clinical benefit assessment, a central aim of recent approaches to value measurement, including value based assessment ...
Angelis, Aris, Kanavos, Panos, Lange, Ansgar   +2 more
core   +1 more source

Emerging role of ARHGAP29 in melanoma cell phenotype switching

Molecular Oncology, EarlyView.
This study gives first insights into the role of ARHGAP29 in malignant melanoma. ARHGAP29 was revealed to be connected to tumor cell plasticity, promoting a mesenchymal‐like, invasive phenotype and driving tumor progression. Further, it modulates cell spreading by influencing RhoA/ROCK signaling and affects SMAD2 activity. Rho GTPase‐activating protein
Beatrice Charlotte Tröster, Melanie Kappelmann‐Fenzl, Anja Katrin Bosserhoff, Nicole Rachinger   +3 more
wiley   +1 more source

The Electronic Health Record Scorecard: A Measure of Utilization and Communication Skills [PDF]

, 2016
As the adoption rate of electronic health records (EHRs) in the United States continues to grow, both providers and patients will need to adapt to the reality of a third actor being present during the visit encounter.
Leamon, Ashley E.
core   +1 more source

Modeling hepatic fibrosis in TP53 knockout iPSC‐derived human liver organoids

Molecular Oncology, EarlyView.
This study developed iPSC‐derived human liver organoids with TP53 gene knockout to model human liver fibrosis. These organoids showed elevated myofibroblast activation, early disease markers, and advanced fibrotic hallmarks. The use of profibrotic differentiation medium further amplified the fibrotic signature seen in the organoids.
Mustafa Karabicici, Soheil Akbari, Ceyda Caliskan, Canan Celiker, Ozden Oz, Leman Binokay, Gökhan Karakulah, Serif Senturk, Esra Erdal   +8 more
wiley   +1 more source

1687O PRIMCAT: A novel approach to informing health technology assessment decision making in Australia [PDF]

, 2023
Fanny Franchini, Karen Trapani, J. Soon, Benjamin Daniels, Peter M. Gillett, Koen Degeling, Marliese Alexander, Y.H. To, Sophie O’Haire, Ou Yang, Stephen B. Fox, Jayesh Desai, Ying Zhang, Benjamin Solomon, Peter Gibbs, Grant A. McArthur, Sallie‐Anne Pearson, M. IJzerman   +17 more
openalex   +1 more source

PYCR1 inhibition in bone marrow stromal cells enhances bortezomib sensitivity in multiple myeloma cells by altering their metabolism

Molecular Oncology, EarlyView.
This study investigated how PYCR1 inhibition in bone marrow stromal cells (BMSCs) indirectly affects multiple myeloma (MM) cell metabolism and viability. Culturing MM cells in conditioned medium from PYCR1‐silenced BMSCs impaired oxidative phosphorylation and increased sensitivity to bortezomib.
Inge Oudaert, Lauren van den Broecke, Osman Aksoy, Judith Lind, Sonia Vallet, Arne Van der Vreken, Gamze Ates, Ann Massie, Ken Maes, Kim De Veirman, Elke De Bruyne, Karin Vanderkerken, Klaus Podar, Eline Menu   +13 more
wiley   +1 more source

Inhibition of CDK9 enhances AML cell death induced by combined venetoclax and azacitidine

Molecular Oncology, EarlyView.
The CDK9 inhibitor AZD4573 downregulates c‐MYC and MCL‐1 to induce death of cytarabine (AraC)‐resistant AML cells. This enhances VEN + AZA‐induced cell death significantly more than any combination of two of the three drugs in AraC‐resistant AML cells.
Shuangshuang Wu, Jianlei Zhao, Aaban Asfar Azmi, Avanti Gupte, Jenna Thibodeau, Shuang Liu, Jinli Yang, Guan Wang, Holly Edwards, Lisa A. Polin, Juiwanna Kushner, Sijana H. Dzinic, Kathryn White, Julie Boerner, Maik Hüttemann, Jay Yang, Yue Wang, Jeffrey W. Taub, Yubin Ge   +18 more
wiley   +1 more source